Skip to main content

ORIGINAL RESEARCH article

Front. Cell. Neurosci.
Sec. Non-Neuronal Cells
Volume 18 - 2024 | doi: 10.3389/fncel.2024.1440409
This article is part of the Research Topic Function and Regulation of Non-Neuronal Cells in the Nervous System View all articles

Discovery of GJC1 as a Prognostic Biomarker in Glioma Cells: Insights into Its Cell-Cycle Relationship and Differential Expression in Non-Neuronal Cells

Provisionally accepted
Xiangtian Ji Xiangtian Ji 1Xin Chen Xin Chen 1Guozhong Lin Guozhong Lin 1Kaiming Ma Kaiming Ma 1Junhua Yang Junhua Yang 2Xiaofang Zhao Xiaofang Zhao 2Suhua Chen Suhua Chen 1Jun Yang Jun Yang 1*
  • 1 Peking University Third Hospital, Haidian, China
  • 2 Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Beijing, China

The final, formatted version of the article will be published soon.

    Background: Gliomas, originating from the most common non-neuronal cells in the brain (glial cells), are the most common brain tumors and are associated with high mortality and poor prognosis. Glioma cells exhibit a tendency to disrupt normal cell-cycle regulation, leading to abnormal proliferation and malignant growth. This study investigated the predictive potential of GJC1 in gliomas and explored its relationship with the cell cycle.Methods: Retrospective analysis of RNA-seq and single-cell sequencing data was conducted using the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases. The differential expression of GJC1 in gliomas with various pathological features and in different nonneuronal cell groups was analyzed. Functional data were examined using gene set variation analysis (GSVA). Furthermore, CellMiner was used to evaluate the relationship between GJC1 expression and predicted treatment response across these databases.Results: GJC1 expression was enriched in high-grade gliomas and 1p/19q non-codeletion gliomas. GJC1 enrichment was observed in classical and mesenchymal subtypes within the TCGA glioma subtype group. In single-cell subgroup analysis, GJC1 expression was higher in glioma tissues compared to other non-neuronal cells. Additionally, the TCGA classical subtype of glioma cells exhibited more GJC1 expression than the other subgroups. GJC1 emerged as an independent prognostic factor for overall survival in glioma. GSVA unveiled potential mechanisms by which GJC1 may impact cell-cycle regulation in glioma. Finally, a significant correlation was observed between GJC1 expression and the sensitivity of multiple anti-cancer drugs.These findings confirmed GJC1 as a novel biomarker and provided insights into the differential gene expression in non-neuronal cells and the impact of the cell cycle on gliomas. Consequently, GJC1 may be used to predict glioma prognosis and has potential therapeutic value.

    Keywords: Glioma, Non-neuronal cells, single-cell RNA sequencing, bioinformatics, cell cycle regulation, Oncology drugs

    Received: 29 May 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Ji, Chen, Lin, Ma, Yang, Zhao, Chen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jun Yang, Peking University Third Hospital, Haidian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.